PMD86 A Systematic Review of Economic Evaluations Conducted for Assessment of Genetic Testing Technologies  by Assasi, N. et al.
cantly lower mean Total scores than controls (54.7 vs. 99.2; P0.0001), Sleep/energy
scores (55.9 vs. 100.0; P0.0001), and Bother/concern scores (54.0 vs. 98.3; P0.0001),
indicating greater health-related quality of life impairment because of nighttime
urination. CONCLUSIONS: The Stanford Sleepiness Scale, Epworth Sleepiness
Scale, and N-QoL all effectively discriminate between participants with OAB symp-
toms and those without OAB symptoms.
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OBJECTIVES: The conventional economic evaluations (EE) methods may be chal-
lenging within the context of genetic testing technologies (GTTs), because: the
main outcome a GTT is information, benefits may occur many years after taking
the test, non-medical harms might be associated with GTTs, and GTTs may also
provide information about the genetic status of the family members of affected
individuals. This study was performed to systematically review the methods used
in EEs included in Health Technology Assessments (HTAs) of GTTs. METHODS: A
systematic search of literature was undertaken to identify HTA reports on GTTs
that included EEs in addition to clinical effectiveness results. Studies were re-
viewed in terms of methods (e.g. type of EE, analytic perspective, cost-effectiveness
analysis), and quality (using QHES instrument).RESULTS:Of 342 identified citations,
13 HTAs consisting of 10 model-based and 3 trial-based EEs were included. More than
50% of the included studies had moderate to low quality scores mainly due to not
reporting information on basic elements of a standard EE and inadequate manage-
ment of uncertainty. Cost-effectiveness analysis (CEA) accounted for 62% of included
studies. 65% of the studies adopted a third party payer perspective, and 60% used a
lifelong time horizon. 75% of CEAs reported intermediate outcomes (e.g. cases-de-
tected). The majority of studies exclusively included technical costs of testing (100%)
and therapeutic or preventive interventions (62%). The most frequent variables tested
in univariate sensitivity analysis included costs (62%), effects (46%) and transition
probabilities (54%). Probabilistic sensitivity analysis was conducted in 31% of studies.
CONCLUSIONS: We found several methodological challenges in the reviewed EEs,
including: identification of a proper analytical perspective, inclusion of wider range
of outcomes and costs, allowing for long-term psychological, ethical and social
impacts of genetic tests, and sufficient management of uncertainty. These issues
should be carefully considered in future EEs of GTTs.
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OBJECTIVES: Suprapubic catheterization (SPT) is a common urologic procedure
performed on an elective and urgent basis. Percutaneous approaches have devel-
oped in an effort to circumvent the need for general/spinal anesthesia, but are not
without risk. Rates of SPT-related bowel injury range from 0.3% to 2.7%. We expe-
rienced 4 cases and reviewed the literature to determine identifiable risk factors for
bowel injury.METHODS:A literature review was performed of all English language
articles listed in PubMed and articles reporting percutaneous SPT placement re-
lated bowel injury were selected. Included in our review are 4 cases in our institu-
tion. Data from articles and our cases was extracted to determine the technique of
SPT placement utilized, underlying risk factors, and nature of bowel injury.
RESULTS: Nineteen papers reported 22 cases of bowel injury as a result of percu-
taneous SPT placement, 2 of which were excluded for insufficient data. Addition-
ally, the 4 cases at our institution were included in the analysis. Small capacity or
thick-walled neurogenic bladders (4/24, 17%), prior abdominal surgery (13/24, 54%),
and pelvic radiation (5/24, 21%) were associated with bowel injury during SPT
placement. Diagnosis of bowel injury was based on history, physical examination
and imaging modalities. Bowel injury had a bimodal presentation, at initial place-
ment (14/24, 58%) and at initial SPT change (10/24, 42%). CONCLUSIONS: Based on
this review we advocate consideration of open SPT placement in patients with
small capacity or thick-walled neurogenic bladders, those in whom the bladder
cannot be distended adequately, prior abdominal/pelvic surgery or radiation, as-
cites. If percutaneous SPT is planned, Trendelenburg positioning and use of ultra-
sound and/or fluoroscopy at time of SPT placement is supported by the literature.
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OBJECTIVES: To compare the prevalence rates of seizure, hydrocephalus and other
clinical conditions before and after a surgical removal of subependymal giant cell
astrocytoma (SEGA) in patients with tuberous sclerosis complex (TSC). METHODS:
A pre-post comparative longitudinal cohort study was conducted based on 3 large
US national healthcare claims databases (2000-2009). TSC patients with a first ob-
served SEGA surgery at age 35 or younger and with continuous health insurance
coverage 1 year before and 1 year after the surgery were selected. The prevalence
rates of seizure, hydrocephalus, and other TSC related clinical conditions, such as
vision disorders, coma, speechlessness, headache, stroke or hemiparesis, cognitive
difficulties, muscle weakness, papillodema, balance disorders, loss of sensation,
nausea and vomiting, depression, anxiety, attention deficit disorders, autism, and
sleep disorders, were estimated and compared between a period of the last 6 pre-
operative months and the first two postoperative periods (the 2nd to 6th postoper-
ative months; 7th to 12th postoperative months). Repeated measures analysis with
bootstrapping re-sampling approach was used for the cross-period comparisons.
RESULTS: The mean age of the select patients (N47) was 11.6 year at their first
observed SEGA surgery; the majority of the patients were male (66%). Statistically
significant postoperative increases in the prevalence rates of seizure (23 26%,
p0.05), hydrocephalus (2126%, p0.05), headache (1719%, p0.05), stroke and
hemiparesis (69%, p0.05), and autism (9%, p0.05) were observed.
CONCLUSIONS: This real-world claim data showed an increase in the risk of some
clinical conditions including seizure and hydrocephalus after a SEGA surgery in
patients with TSC. Further research to explore any possible causal relationship
between these risk increases and SEGA surgery through prospective studies or
registries is needed.
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OBJECTIVES: To examine the prevalence rates of surgical complications among
tuberous sclerosis complex (TSC) patients with surgical removal of subpendymal
giant cell astrocytoma (SEGA). METHODS: Based on 3 US national health care
claims databases (20002009), a retrospective cohort study was conducted in TSC
patients who had a SEGA surgery at age 35 or younger, and were under continuous
health insurance coverage 1 year before and 1 year after the surgery. A SEGA sur-
gery was identified by a healthcare claim that simultaneously had a TSC diagnosis
code, a benign brain tumor diagnosis code and a procedure code of removing a
benign tumor from cerebral ventricle system. The surgical complications exam-
ined in the study included surgical procedure complications, nervous system com-
plications, surgical misadventures, postoperative infection, subdural empyemas,
and epidural abscess. The prevalence rates of these conditions were estimated for
the first postoperative year. RESULTS: Approximately 47 TSC patients had at least
one SEGA surgery. The mean age of patients at their 1st observed SEGA surgery was
11.6 years. The majority of patients (66%) were male. The prevalence rates of sur-
gical complications in the 1st postoperative year were 34% for surgical procedure
complications, 17% for subdural empyemas, 12.8% for nervous system complica-
tions, 6% for postoperative infection, 2% for epidural abscess, and 0% for surgical
misadventures respectively. CONCLUSIONS: In this real-world claim database
analysis, we observed that a portion of TSC patients experienced surgical compli-
cations within first year after their SEGA surgeries. Further research is needed to
better understand the causes of this surgical outcome.
PSU4
POSTOPERATIVE PREVALENCE RATE OF SUBEPENDYMAL GIANT CELL
ASTROCYTOMA (SEGA) DIAGNOSIS AND REPEATED SEGA SURGERY IN
PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX: A REAL-WORLD NATIONAL
RETROSPECTIVE COHORT STUDY
Sun P1, Liu Z2, Rogerio J2, Guo A2, Garay C2, Kohrman M3
1Kailo Research Group, Fishers, IN, USA, 2Novartis Pharmaceuticals Corporation, East Hanover,
NJ, USA, 3University of Chicago, Chicago, IL, USA
OBJECTIVES: To examine the postoperative prevalence of subependymal giant cell
astrocytoma (SEGA) diagnosis and repeated SEGA surgeries among patients with
tuberous sclerosis complex (TSC) who had an initial SEGA surgery. METHODS:
Based on three US national health claims databases (20002009), we conducted a
retrospective cohort study with TSC patients who had a first observed SEGA sur-
gery at age 35 or younger and were under continuous health insurance coverage 1
year before and 1 year after their 1st SEGA surgery. A SEGA surgery was defined as
having 1) a TSC diagnosis code, 2) a benign brain tumor diagnosis code, and 3) a
procedure code for removing a benign tumor from cerebral ventricle system. A
SEGA diagnosis is defined as 1) and 2). The prevalence rates of postoperative SEGA
diagnosis and repeated SEGA surgery were estimated for a period from the 3rd
through 6th postoperative month and a period from the 7th through 12th postoper-
ative month respectively. RESULTS: The select patients (N47) had mean age of
11.6 years (at the 1st SEGA surgery) with 66% males. After the 1st observed SEGA
surgery, postoperative prevalence rates of SEGA diagnosis was 34% in the period
from the 3rd to 6th postoperative month and 26% in the period from the 7th to 12th
postoperative month. About 49% patients had a repeated SEGA surgery in their 1st
postoperative year. CONCLUSIONS: In the real-world setting, TSC patients with
SEGA surgery may experience repeated SEGA surgeries or/and still have SEGA di-
agnoses within the first postoperative year. Further research on the effectiveness
of SEGA surgery via prospective studies or registries is needed to improve care in
TSC patients with SEGA.
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